CureVac N.V. (CVAC)
NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 3.6400 |
| Open | 3.6900 |
| Bid | 3.7000 x 100 |
| Ask | 3.7700 x 100 |
| Day's range | 3.6000 - 3.7400 |
| 52-week range | 2.2150 - 10.1400 |
| Volume | |
| Avg. volume | 1,322,625 |
| Market cap | 834.418M |
| Beta (5Y monthly) | 2.64 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.3200 |
| Earnings date | 15 Aug 2024 - 19 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 8.39 |
ZacksCureVac (CVAC) Upgraded to Buy: What Does It Mean for the Stock?
CureVac (CVAC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Simply Wall St.An Intrinsic Calculation For CureVac N.V. (NASDAQ:CVAC) Suggests It's 47% Undervalued
Key Insights The projected fair value for CureVac is US$5.84 based on 2 Stage Free Cash Flow to Equity CureVac is...
ZacksGSK Buys Flu, COVID mRNA Jab Rights From Partner CureVac
GSK revamps its existing collaboration deal with partner CureVac, converting it from a collaboration deal into a licensing agreement related to mRNA vaccine candidates for COVID-19 and influenza.
© 2024 Yahoo. All rights reserved.